BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

10 4 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

25 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

15 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

12 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

01 3 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Termination of Proposed Public Offering

13 2 2024 08:00:43 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

12 2 2024 06:14:31 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering

08 2 2024 15:01:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

06 2 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

05 2 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

12 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

11 12 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

30 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

14 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

08 11 2023 06:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

06 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

31 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

30 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

25 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

10 10 2023 06:00:00 提供 Nasdaq GlobeNewswire